ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,047 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 1-25 of 1,000 matching filings.

Per page
25
Current page
1
6-K File 001-11960

ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT

Filing date
29 Sep 2026
Reporting date
29 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TRIXEO APPROVED IN EU FOR ASTHMA

Filing date
23 Sep 2026
Reporting date
23 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP

Filing date
21 Sep 2026
Reporting date
21 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC

Filing date
21 Sep 2026
Reporting date
21 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
18 Sep 2026
Reporting date
18 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
15 Sep 2026
Reporting date
15 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
15 Sep 2026
Reporting date
15 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON SERENA-4 PHASE III TRIAL

Filing date
14 Sep 2026
Reporting date
14 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG

Filing date
08 Sep 2026
Reporting date
08 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER

Filing date
08 Sep 2026
Reporting date
08 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ADMISSION OF FURTHER SECURITIES TO TRADING

Filing date
01 Sep 2026
Reporting date
01 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Sep 2026
Reporting date
01 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING

Filing date
01 Sep 2026
Reporting date
01 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC

Filing date
01 Sep 2026
Reporting date
01 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTORATE CHANGE

Filing date
01 Sep 2026
Reporting date
01 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY

Filing date
01 Sep 2026
Reporting date
01 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG

Filing date
01 Sep 2026
Reporting date
01 Sep 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS

Filing date
27 Aug 2026
Reporting date
27 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING

Filing date
25 Aug 2026
Reporting date
25 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
19 Aug 2026
Reporting date
19 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER

Filing date
17 Aug 2026
Reporting date
17 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL

Filing date
17 Aug 2026
Reporting date
17 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG

Filing date
17 Aug 2026
Reporting date
17 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ADMISSION OF FURTHER SECURITIES TO TRADING

Filing date
03 Aug 2026
Reporting date
03 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
03 Aug 2026
Reporting date
03 Aug 2026
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .